Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy.

Shah DR, Shah RR, Morganroth J.

Drug Saf. 2013 Jun;36(6):413-26. doi: 10.1007/s40264-013-0050-x. Review.

PMID:
23620170
2.
3.

Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.

Kato R, Obara W, Matsuura T, Kato Y, Iwasaki K, Fujioka T.

Jpn J Clin Oncol. 2014 May;44(5):479-85. doi: 10.1093/jjco/hyu018. Epub 2014 Mar 30.

4.

Tyrosine kinases as targets in cancer therapy - successes and failures.

Traxler P.

Expert Opin Ther Targets. 2003 Apr;7(2):215-34. Review.

PMID:
12667099
5.

Different treatment orders achieved similar clinical results: a retrospective study for retreatment of epidermal growth factor receptor tyrosine kinase inhibitors in 120 patients with non-small-cell lung cancer.

Tang C, Gao H, Li X, Liu Y, Li J, Qin H, Wang W, Qu L, An J, Yang S, Liu X.

J Cancer Res Clin Oncol. 2014 Mar;140(3):427-33. doi: 10.1007/s00432-014-1582-x. Epub 2014 Jan 9.

PMID:
24401995
6.

Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).

Shah RR, Morganroth J, Shah DR.

Drug Saf. 2013 May;36(5):295-316. doi: 10.1007/s40264-013-0047-5. Review.

PMID:
23620167
7.

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.

Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.

Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.

8.

Pulmonary toxicities of tyrosine kinase inhibitors.

Peerzada MM, Spiro TP, Daw HA.

Clin Adv Hematol Oncol. 2011 Nov;9(11):824-36. Review.

PMID:
22252615
9.

Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.

Lee JK, Hahn S, Kim DW, Suh KJ, Keam B, Kim TM, Lee SH, Heo DS.

JAMA. 2014 Apr 9;311(14):1430-7. doi: 10.1001/jama.2014.3314.

PMID:
24715074
10.

Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.

Erdem L, Giovannetti E, Leon LG, Honeywell R, Peters GJ.

Curr Top Med Chem. 2012;12(15):1649-59. Review.

PMID:
22978339
11.

Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies.

Hojjat-Farsangi M.

Int J Mol Sci. 2014 Aug 8;15(8):13768-801. doi: 10.3390/ijms150813768. Review.

12.

Targeting tyrosine-kinases in ovarian cancer.

Morotti M, Becker CM, Menada MV, Ferrero S.

Expert Opin Investig Drugs. 2013 Oct;22(10):1265-79. doi: 10.1517/13543784.2013.816282. Epub 2013 Jul 2. Review.

PMID:
23815710
13.
14.

Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.

Ciardiello F, Caputo R, Damiano V, Caputo R, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR, Tortora G.

Clin Cancer Res. 2003 Apr;9(4):1546-56.

15.

Effect of tyrosine kinase inhibitors on wound healing and tissue repair: implications for surgery in cancer patients.

Shah DR, Dholakia S, Shah RR.

Drug Saf. 2014 Mar;37(3):135-49. doi: 10.1007/s40264-014-0139-x. Review.

PMID:
24526268
16.

[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].

Török S, Cserepes T M, Rényi-Vámos F, Döme B.

Magy Onkol. 2012 Sep;56(3):199-208. Epub 2012 Aug 1. Review. Hungarian.

17.

Epidermal growth factor receptor inhibition strategies in oncology.

Harari PM.

Endocr Relat Cancer. 2004 Dec;11(4):689-708. Review.

18.

Clinical research of EGFR inhibitors and related dermatologic toxicities.

Perez-Soler R, Van Cutsem E.

Oncology (Williston Park). 2007 Oct;21(11 Suppl 5):10-6.

19.

Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors.

Terada T, Noda S, Inui K.

Pharmacol Ther. 2015 Aug;152:125-34. doi: 10.1016/j.pharmthera.2015.05.009. Epub 2015 May 11. Review.

20.

HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors.

Gusenbauer S, Vlaicu P, Ullrich A.

Oncogene. 2013 Aug 15;32(33):3846-56. doi: 10.1038/onc.2012.396. Epub 2012 Oct 8.

PMID:
23045285
Items per page

Supplemental Content

Write to the Help Desk